 |
|
Neuromics and Neurological Disease
Roger N. Rosenberg, MD, Editor
Arch Neurol. 2008;65(3):307-308.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Neuromics, the analysis of genomic DNA for risk association with a neurological disease, has achieved considerable success recently. An increased risk for amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), restless leg syndrome (RLS), and multiple sclerosis has been associated with polymorphisms in specific genes. These observations are truly significant advances in the appreciation of the causation of inherited, complex polygenetic, multifactorial neurological diseases. They have been made possible by the publication of the human genome and haplotype studies (HapMap analyses). Neurome-wide association studies will increase in the future and we plan on devoting an increased interest in them, as they provide a new detailed level of analyses to achieve a clearer understanding of multigene interactions responsible for neurological disease. For the time being, most of these neurome-wide analyses will not have direct clinical relevance and will not directly affect patient care. Eventually, and perhaps quite . . . [Full Text of this Article]AUTHOR INFORMATION
RELATED ARTICLES
Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis
Esther Byun, Stacy J. Caillier, Xavier Montalban, Pablo Villoslada, Oscar Fernández, David Brassat, Manuel Comabella, Joanne Wang, Lisa F. Barcellos, Sergio E. Baranzini, and Jorge R. Oksenberg
Arch Neurol. 2008;65(3):337-344.
ABSTRACT
| FULL TEXT
Genome-Wide Association Studies in Alzheimer Disease
Stephen C. Waring and Roger N. Rosenberg
Arch Neurol. 2008;65(3):329-334.
ABSTRACT
| FULL TEXT
|
